^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PH-3861
i
Other names: PH-3861, Intasyl targeting BRD4 and PD-1, PH-894/mPH-762
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Phio Pharma
Drug class:
PD1 inhibitor, BRD4 inhibitor
Related drugs:
over3years
[VIRTUAL] Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors (ESMO 2021)
These data show that, in addition to eliciting stable complete resolution, dual-targeting IT treatment with INTASYL PH-894/mPH-762 engenders durable systemic anti-tumor immunity and supports a planned clinical study to start later this year in France.
Preclinical
|
PD-1 (Programmed cell death 1) • BRD4 (Bromodomain Containing 4)
|
PH-3861
over3years
[VIRTUAL] INTASYL self-delivering RNAi therapy specifically dual-targeting BRD4 and PD-1 to elicit complete tumor responses and evidence of synergy in a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice. (ASCO 2021)
Positive control groups received systemic (IP) (+)-JQ-1 (13.33mg/dose; qdx5), anti-mouse PD-1 antibody (75 µg; Days 1, 3, 7, 10, 14), or both treatments . These data demonstrate proof-of-concept of the therapeutic potential of rational dual-targeted INTASYL provided as single formulation in vivo, suggesting potential for meaningful clinical therapeutic impact.
Preclinical
|
PD-1 (Programmed cell death 1) • BRD4 (Bromodomain Containing 4)
|
JQ-1 • PH-3861
Share via
